AR078278A1 - ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. - Google Patents
ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.Info
- Publication number
- AR078278A1 AR078278A1 ARP100103292A ARP100103292A AR078278A1 AR 078278 A1 AR078278 A1 AR 078278A1 AR P100103292 A ARP100103292 A AR P100103292A AR P100103292 A ARP100103292 A AR P100103292A AR 078278 A1 AR078278 A1 AR 078278A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- same
- hepcidine
- tiazol
- anemias
- Prior art date
Links
- 206010022971 Iron Deficiencies Diseases 0.000 title 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940066919 hepcidin Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula general (1), caracterizados porque X está elegido entre S y O, R1 está elegido del grupo que comprende: hidrogeno, amino opcionalmente sustituido, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; o R2 y R3 pueden ser iguales o distintos entre sí y representan: hidrogeno, alquilo opcionalmente sustituido, los radicales alquil-, aril- o heterociclilsulfonilo opcionalmente sustituidos alcoxicarbonilo opcionalmente sustituido acilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; o sus sales farmacéuticamente aceptables.Claim 1: Compounds of the general formula (1), characterized in that X is selected from S and O, R1 is selected from the group comprising: hydrogen, optionally substituted amino, optionally substituted alkyl, optionally substituted alkenyl alkenyl, optionally substituted alkynyl , optionally substituted aryl, optionally substituted heterocyclyl; or R2 and R3 may be the same or different from each other and represent: hydrogen, optionally substituted alkyl, optionally substituted alkyl-, aryl- or heterocyclylsulfonyl radicals optionally substituted alkoxycarbonyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl; or its pharmaceutically acceptable salts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09169861 | 2009-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078278A1 true AR078278A1 (en) | 2011-10-26 |
Family
ID=41582084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103292A AR078278A1 (en) | 2009-09-09 | 2010-09-08 | ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR078278A1 (en) |
| TW (1) | TW201111379A (en) |
| WO (1) | WO2011029832A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN105130948A (en) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | Pharmaceutical compositions and administrations thereof |
| EP3424534B1 (en) | 2014-04-15 | 2021-06-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EA039916B1 (en) * | 2015-10-23 | 2022-03-28 | Вифор (Интернациональ) Аг | Novel ferroportin inhibitors |
| CN114668761B (en) * | 2015-10-23 | 2025-08-01 | 威佛（国际）股份公司 | Novel inhibitors of membrane iron transport proteins |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| CN110198935B (en) | 2017-01-23 | 2022-05-31 | 卡登特治疗公司 | Potassium Channel Modulator |
| JOP20180036A1 (en) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | Salts for new fruortin inhibitors |
| MA53978A (en) | 2018-10-22 | 2021-09-01 | Cadent Therapeutics Inc | CRYSTALLINE FORMS OF POTASSIUM CHANNEL MODULATORS |
| ES2934492T3 (en) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Ferroportin inhibitors and methods of use |
| CN114761013A (en) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | Methods of treating myelofibrosis and related disorders |
| CA3172806A1 (en) | 2020-03-24 | 2021-09-30 | Stefan Reim | Process for the production of ferroportin inhibitors |
| JP2023528223A (en) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | Anti-Hemoduvelin (HJV) Antibodies for Treating Myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| TW202304896A (en) | 2021-04-22 | 2023-02-01 | 瑞士商威佛（國際）股份有限公司 | Modified ferroportin inhibitors |
| KR20240067094A (en) | 2021-09-21 | 2024-05-16 | 비포르 (인터내셔날) 아게 | N-substituted ferroportin inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| ATE427114T1 (en) | 2001-05-25 | 2009-04-15 | Inst Nat Sante Rech Med | USE OF HEPCIDIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF IRON HOMEOSTASIS DISORDERS |
| AU2003295644A1 (en) | 2002-11-19 | 2004-07-22 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| JP2008007405A (en) * | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | Carboxamide derivative |
| US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| EP1960382A1 (en) | 2005-11-03 | 2008-08-27 | ChemBridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| CA2663581C (en) | 2006-09-21 | 2016-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
| CA2676036A1 (en) | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| CL2008000666A1 (en) | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | COMPOUNDS DERIVED FROM SUBSTITUTED TRICYCLES, INHIBITORS OF THE DIVALENT-1 METAL TRANSPORTER; AND USE TO TREAT AN ILLNESS ASSOCIATED WITH AN IRON DISORDER. |
| AR065785A1 (en) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | BIARETO AND BIHETEROARILE COMPOUNDS OF UTILITY IN THE TREATMENT OF IRON DISORDERS |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| TWI425945B (en) | 2007-05-28 | 2014-02-11 | Seldar Pharma Inc | Tetrahydroisoquinolin-1-one derivatives or salt thereof |
| WO2008151288A2 (en) | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
| GR1006896B (en) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | A process for producing a peptide hormone. |
| JP2010539969A (en) | 2007-10-02 | 2010-12-24 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | Antigen-binding protein with specificity for human hepcidin |
| AR069062A1 (en) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | ANTI-HEPCIDINE ANTIBODY |
| US20120094974A1 (en) | 2008-06-17 | 2012-04-19 | Wei Chen | Smoothened receptor modulators |
-
2010
- 2010-09-08 WO PCT/EP2010/063146 patent/WO2011029832A1/en not_active Ceased
- 2010-09-08 TW TW099130304A patent/TW201111379A/en unknown
- 2010-09-08 AR ARP100103292A patent/AR078278A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201111379A (en) | 2011-04-01 |
| WO2011029832A1 (en) | 2011-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078278A1 (en) | ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. | |
| ECSP19026680A (en) | BENZO [b] THIOPHENE COMPOUNDS AS STING AGONISTS | |
| UY33921A (en) | N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTIRIDINONES | |
| CR20120591A (en) | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
| NI201200184A (en) | MORPHOLINOPYRIMIDINES AND THEIR USE IN THERAPY | |
| UY31940A (en) | SUBSTITUTED DERIVATIVES OF 4,5- (SUBSTITUTED-PIRIDIN-3-IL) -1-METHYL-1H-INDOL, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHOS, ROTÁMEROS, PRO-DRUGS, ANANTIOMERS, HYDRATES, SOLVATOS OF THE SAME AND COMPOSITIONS | |
| UY31254A1 (en) | SUBSTITUTED DERIVATIVES OF N4- (5-METHYL-1H-PIRAZOL-3-IL) - 1,3,5-TRIAZINA-2,4-DIAMINE, THEIR ENANTIOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS, PREPARATION PROCESSES AND APPLICATIONS | |
| MX373711B (en) | Sulfamoylarylamides and their use as drugs for the treatment of hepatitis B. | |
| CR9459A (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME | |
| CL2008003284A1 (en) | Compounds derived from 4-benzylamino-1-carboxyacyl-pyridine, cetp inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; and use in the treatment of metabolic, atherosclerosis and cardiovascular diseases, among others. | |
| SV2010003598A (en) | TIAZOL DERIVATIVES USED AS PI 3-CINASA INHIBITORS | |
| CL2011000589A1 (en) | Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer. | |
| ECSP109903A (en) | DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | |
| ECSP10010693A (en) | PIRAZOLIC COMPOUNDS 436 | |
| UY32203A (en) | AMINO PIRIMIDINAS AND ITS USE IN THERAPY | |
| UY31127A1 (en) | METABOTROPIC RECEIVER OXYADAZOL LIGANDS FOR GLUTAMATE AND ITS USE AS POTENTIALS - 841 | |
| ECSP10010419A (en) | UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211 | |
| CY1117792T1 (en) | COMPETITORS TOY TRPV4 | |
| ECSP12012161A (en) | Compounds as Bradykinin-b1 antagonists | |
| UY31885A (en) | DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS. | |
| UY35275A (en) | AMINOPIRAZINE DERIVATIVES | |
| CO6351793A2 (en) | \ "DERIVATIVES OF INDOL MACROCICLICOS USEFUL AS INHIBITORS OF THE HEPATITIS VIRUS | |
| ECSP099216A (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| SV2009003389A (en) | PIRIDO COMPOUNDS [2,3-D] PIRIMIDINA-7-ONA AS P13K-ALFA INHIBITORS FOR CANCER TREATMENT | |
| PE20141940A1 (en) | TRICYCLIC COMPOUNDS, COMPOSITIONS THAT INCLUDE THEM, AND USES OF THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |